PD-1抑制剂替雷利珠单抗治疗晚期恶性肿瘤的药理作用与临床评价

Pharmacological Effects and Clinical Evaluation of PD-1 Inhibitor of Tislelizumab in the Treatment of Advanced Malignant Tumors

摘要: 近年来, 免疫治疗在恶性肿瘤领域取得了革命性突破, 越来越多的新型免疫检查点抑制剂问世, 彻底改变了恶性肿瘤的一线、二线和后线治疗选择。替雷利珠单抗是中国自主研发的PD-1抑制剂, 该药在经典型霍奇金淋巴瘤、尿路上皮癌、非小细胞肺癌、肝细胞癌、食管鳞状细胞癌和胃癌/胃食管交界癌等肿瘤治疗中均表现出良好的抗肿瘤潜力和安全性。本文就替雷利珠单抗的结构与作用机制、药效学与药代动力学、临床研究及不良反应等方面的最新进展进行阐述, 以期为临床医师提供借鉴和参考。

Abstract: In recent years, immunotherapy has made breakthroughs in the field of malignant tumors, and more and more novel immune checkpoint inhibitors have been developed, revolutionizing the first-line, second-line and post-line treatment options for malignant tumors. Tislelizumab is a domestically developed inhibitor of programmed death-1 (PD-1). The drug has shown good antitumor potential and safety in classical Hodgkin's lymphoma, uroepithelial carcinoma, non-small cell lung cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma and gastric cancer/gastroesophageal junction carcinoma. In this review, the structure and mechanism of action, pharmacodynamics and pharmacokinetics, clinical research and adverse reactions of tislelizumab are reviewed to provide reference for clinical application.